AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+7.02%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$5.38B
AUM Growth
+$5.38B
(+6.7%)
Cap. Flow
+$11.7M
Cap. Flow
% of AUM
0.22%
Top 10 Holdings %
Top 10 Hldgs %
92.84%
Holding
124
New
16
Increased
27
Reduced
16
Closed
13
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$25.4M |
| 2 |
Incyte
INCY
|
$9.47M |
| 3 |
argenx
ARGX
|
$9.2M |
| 4 |
AXDX
Accelerate Diagnostics
AXDX
|
$7.86M |
| 5 |
Denali Therapeutics
DNLI
|
$7.82M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$50.8M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$18.6M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$12.4M |
| 4 |
Neurocrine Biosciences
NBIX
|
$11.6M |
| 5 |
RXDX
Ignyta, Inc.
RXDX
|
$11.1M |
Sector Composition
| 1 | Consumer Staples | 53.33% |
| 2 | Consumer Discretionary | 24.25% |
| 3 | Healthcare | 21.69% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Seres Therapeutics
MCRB
$162M
| $3.04M | 0.05% |
300,000
-250,000
| -45% | -$2.54M |
|
52
Halozyme
HALO
$8.75B
| $3.04M | 0.05% |
+150,000
| New | +$3.04M |
|
|
CCXI
53
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.98M | 0.04% |
500,000
| – | – |
|
|
CLLS
54
Cellectis
CLLS
$260M
| $2.92M | 0.04% |
100,000
| – | – |
|
55
Corbus Pharmaceuticals
CRBP
$121M
| $2.84M | 0.04% |
400,000
+250,000
| +167% | +$1.77M |
|
|
AKAO
56
DELISTED
Achaogen, Inc.
AKAO
| $2.69M | 0.04% |
250,000
| – | – |
|
57
BioCryst Pharmaceuticals
BCRX
$1.74B
| $2.46M | 0.04% |
500,000
-150,000
| -23% | -$737K |
|
|
CMRX
58
DELISTED
Chimerix, Inc.
CMRX
| $2.32M | 0.03% |
500,000
| – | – |
|
59
Xencor
XNCR
$594M
| $2.19M | 0.03% |
100,000
| – | – |
|
|
ACHN
60
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $2.16M | 0.03% |
750,000
-250,000
| -25% | -$720K |
|
|
JNCE
61
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.91M | 0.03% |
150,000
-50,000
| -25% | -$638K |
|
62
MacroGenics
MGNX
$121M
| $1.9M | 0.03% |
100,000
-100,000
| -50% | -$1.9M |
|
|
MRTX
63
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.83M | 0.03% |
+100,000
| New | +$1.83M |
|
|
ATYR
64
aTyr Pharma
ATYR
$560M
| $1.75M | 0.03% |
500,000
+250,000
| +100% | +$875K |
|
|
MRNS
65
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.63M | 0.02% |
+200,000
| New | +$1.63M |
|
66
Krystal Biotech
KRYS
$4.35B
| $1.58M | 0.02% |
150,000
+50,000
| +50% | +$526K |
|
67
Editas Medicine
EDIT
$225M
| $1.54M | 0.02% |
+50,000
| New | +$1.54M |
|
68
Kura Oncology
KURA
$732M
| $1.53M | 0.02% |
100,000
| – | – |
|
69
Minerva Neurosciences
NERV
$16.8M
| $1.52M | 0.02% |
251,300
| – | – |
|
|
KDNY
70
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.5M | 0.02% |
200,000
| – | – |
|
71
Rhythm Pharmaceuticals
RYTM
$6.75B
| $1.45M | 0.02% |
+50,000
| New | +$1.45M |
|
72
Syndax Pharmaceuticals
SNDX
$1.39B
| $1.31M | 0.02% |
150,000
-2,920
| -2% | -$25.6K |
|
73
CRISPR Therapeutics
CRSP
$4.82B
| $1.17M | 0.02% |
+50,000
| New | +$1.17M |
|
|
TRIL
74
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.09M | 0.02% |
+150,000
| New | +$1.09M |
|
75
Viridian Therapeutics
VRDN
$1.59B
| $1.04M | 0.02% |
100,000
| – | – |
|